PFE Pfizer Inc.
Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Company profile
Ticker
PFE
Exchange
Website
CEO
Albert Bourla
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
SEC CIK
Corporate docs
Calendar
7 Nov 19
25 Feb 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Sep 19 | Jun 19 | Mar 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | 12.68B | 13.26B | 13.12B | 13.98B | |
| Net income | 7.68B | 5.05B | 3.88B | -393M | |
| Diluted EPS | 1.36 | 0.89 | 0.68 | -0.05 | |
| Net profit margin | 60.57% | 38.04% | 29.61% | -2.81% | |
| Operating income* | 11.13B | 4.52B | 4.68B | -588M | |
| Net change in cash | 1B | -153M | 798M | -2.42B | |
| Cash on hand | 2.79B | 1.78B | 1.94B | 1.14B | |
| Cost of revenue | 2.6B | 2.58B | 2.43B | 3.08B |
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
|---|---|---|---|---|---|
| Revenue | 53.65B | 52.55B | 52.82B | ||
| Net income | 11.15B | 21.31B | 7.22B | 6.96B | |
| Diluted EPS | 1.87 | 3.52 | 1.17 | 1.11 | |
| Net profit margin | 20.79% | 40.55% | 13.66% | ||
| Operating income* | 13.17B | 13.53B | 9.51B | 10.14B | |
| Net change in cash | -203M | -1.25B | -1.05B | 298M | |
| Cash on hand | 1.14B | 1.34B | 2.6B | 3.64B | |
| Cost of revenue | 11.25B | 11.23B | 12.32B | 9.65B |
Financial data from Pfizer earnings reports. *Asterisk values are approximate.
Institutional ownership Q4 2019
70.9% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 2411 |
| Opened positions | 260 |
| Closed positions | 120 |
| Increased positions | 980 |
| Reduced positions | 931 |
13F shares |
Current |
|---|---|
| Total value | 1.49T |
| Total shares | 3.92B |
| Total puts | 28.95M |
| Total calls | 25.65M |
| Total put/call ratio | 1.1 |
Largest owners |
Shares | Value |
|---|---|---|
| Vanguard | 449.96M | $17.63B |
| BLK BlackRock | 426.23M | $16.7B |
| STT State Street | 291.79M | $11.43B |
| Wellington Management | 193.73M | $7.59B |
| Capital World Investors | 188.72M | $7.39B |
| BAC Bank of America | 98.9M | $3.88B |
| Geode Capital Management | 89.04M | $3.48B |
| NTRS Northern Trust | 71.18M | $2.79B |
| BK Bank Of New York Mellon | 59.76M | $2.34B |
| N Price T Rowe Associates | 59.24M | $2.32B |
Financial report summary
?Competition
Akorn • TherapeuticsMD • GT Biopharma • Church & Dwight • Teligent • Cypress Bioscience • Celldex Therapeutics • Poniard Pharmaceuticals • Imclone Systems • Acura Pharmaceuticals
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
8th grade Avg
|
|
New words:
abandoned, abrocitinib, adjudicated, adjudication, akcea, amlodipine, antisense, attachment, BEACON, bidder, binimetinib, Braftovi, broad, cap, CDI, Chapel, checkpoint, CHMP, clearance, College, confidential, conveyed, copay, copy, creativity, Creek, database, demerger, derecognized, encorafenib, Fabre, FCPA, Glenmark, globulin, heart, Hill, hip, HIPAA, immunosuppression, incidence, infection, Inquiry, introduction, JV, Kit, knee, Likewise, LLP, locked, lymphoproliferative, Mektovi, metabolic, Missouri, NaN, Neulasta, nonsteroidal, OA, Octagam, Panzyga, pegfilgrastim, percent, pharmacovigilance, Pierre, polyneuropathy, PRAC, principle, procedure, qualification, Relpax, Rodino, Russian, Sanford, SC, slightly, superseded, tied, tumor, unamortized, uncertainty, unvested, urgency, Utah, VBP, viii
Financial reports
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
28 Feb 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
9 Aug 18
10-Q
2018 Q1
Quarterly report
10 May 18
10-K
2017 FY
Annual report
22 Feb 18
10-Q
2017 Q3
Quarterly report
9 Nov 17
10-Q
2017 Q2
Quarterly report
10 Aug 17
Current reports
8-K
Other Events
11 Feb 20
8-K
Pfizer Reports Fourth-quarter and Full-year 2019 Results
28 Jan 20
8-K
Pfizer and Mylan Announce Two Future Viatris Board Members
19 Dec 19
8-K
Pfizer Reports Third-quarter 2019 Results
29 Oct 19
8-K
Departure of Directors or Certain Officers
27 Sep 19
8-K
Pfizer Announces Closing of Joint Venture with Glaxosmithkline to Create a Premier Global Consumer Healthcare Company
5 Aug 19
8-K
Pfizer Reports Second-quarter 2019 Results
29 Jul 19
8-K
Entry into a Material Definitive Agreement
29 Jul 19
8-K
Scott Gottlieb Elected to Pfizer’s Board of Directors
27 Jun 19
8-K
Regulation FD Disclosure
17 Jun 19
Registration and prospectus
425
Business combination disclosure
30 Jan 20
425
Business combination disclosure
16 Jan 20
425
Business combination disclosure
15 Jan 20
425
Business combination disclosure
18 Dec 19
425
Business combination disclosure
12 Nov 19
425
Business combination disclosure
31 Oct 19
425
Business combination disclosure
10 Sep 19
425
Business combination disclosure
4 Sep 19
425
Business combination disclosure
30 Aug 19
S-8
Registration of securities for employees
9 Aug 19
Proxies
PX14A6G
Letter to shareholders
8 Apr 19
DEFA14A
Additional proxy soliciting materials
2 Apr 19
PX14A6G
Letter to shareholders
21 Mar 19
DEFA14A
Additional proxy soliciting materials
14 Mar 19
DEF 14A
Definitive proxy
14 Mar 19
PX14A6G
Letter to shareholders
18 Apr 18
DEFA14A
Additional proxy soliciting materials
6 Apr 18
PX14A6G
Letter to shareholders
6 Apr 18
DEF 14A
Definitive proxy
15 Mar 18
DEFA14A
Additional proxy soliciting materials
15 Mar 18
Other
CT ORDER
Confidential treatment order
15 Mar 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
31 May 17
CERTNYS
Certification of approval for NYSE listing
7 Mar 17
NO ACT
No action letter
10 Feb 17
NO ACT
No action letter
31 Jan 17
NO ACT
No action letter
26 Jan 17
NO ACT
No action letter
10 Jan 17
NO ACT
No action letter
27 Dec 16
SD
Conflict minerals disclosure
31 May 16
Ownership
SC 13G
Beneficial ownership report
14 Feb 20
SC 13G
Beneficial ownership report
14 Feb 20
SC 13G
Pfizer Inc
13 Feb 20
SC 13G/A
Pfizer Inc
12 Feb 20
SC 13G/A
Pfizer Inc
5 Feb 20
SC 13G
CONTRAFECT Corp
16 Dec 19
SC 13G
Cortexyme, Inc.
22 May 19
SC 13G
NextCure, Inc.
22 May 19
SC 13G
Pfizer Inc
14 Feb 19
SC 13G/A
Rhythm Pharmaceuticals, Inc.
13 Feb 19
Patents
GRANT
Utility
Substituted dihydroisoquinolinone compounds
25 Feb 20
Inventors: Michael Raymond Collins, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
GRANT
Utility
Muteins of clotting factor VIII
25 Feb 20
The present disclosure provides muteins of FVIII to which a biocompatible polymer may be attached to increase the circulatory half-life of the muteins, as well as conjugates of such muteins and biocompatible polymers.
GRANT
Utility
Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
25 Feb 20
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
APP
Utility
SGLT-2 Inhibitors for Treating Metabolic Disorders In Patients with Renal Impairment or Chronic Kidney Disease
20 Feb 20
The present invention relates to certain SGLT-2 inhibitors, such as ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof, for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
APP
Utility
Therapeutic Polymeric Nanoparticles Comprising Lipids and Methods of Making and Using Same
20 Feb 20
The present disclosure generally relates to therapeutic nanoparticles.